66572-56-3

Basic information

• Product Name: 2-Bromopyridine-4-carboxylic acid
• Synonyms: IFLAB-BB F1926-0035;2-BROMOPYRIDINE-4-CARBOXYLIC ACID;2-BROMOISONICOTINIC ACID;2-BROMO-4-PYRIDINECARBOXYLIC ACID;4-PYRIDINECARBOXYLIC ACID, 2-BROMO-;RARECHEM AL BE 1524;2-bromo-4-picolinic acid;2-BROMO-4-PYRIDINECARBOXYLIC ACID / 2-BROMOISONICOTINIC ACID
• CAS NO: 66572-56-3
• Molecular Formula: C₆H₄BrNO₂
• Molecular Weight: 202.01
• EINECS: -0
• Product Categories: blocks;Bromides;Carboxes;Pyridines;pyridine derivative;pharmacetical;Carboxylic Acids;Pyridine;Carboxylic Acids;Picolinic acid series;Heterocycle-Pyridine series
• Mol File: 66572-56-3.mol

Chemical Properties

• Melting Point: 229-231°C
• Boiling Point: 447.241 °C at 760 mmHg
• Flash Point: 224.3 °C
• Appearance: White/Crystals or Crystalline Powder
• Density: 1.813 g/cm³
• Vapor Pressure: 8.78E-09mmHg at 25°C
• Storage Temp.: Keep Cold
• PKA: 2.98±0.10(Predicted)
• BRN: 471895
• CAS DataBase Reference: 2-Bromopyridine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromopyridine-4-carboxylic acid(66572-56-3)
• EPA Substance Registry System: 2-Bromopyridine-4-carboxylic acid(66572-56-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 66572-56-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Bromopyridine-4-carboxylic acid is used as a building block for the synthesis of various organic compounds. Its unique structure allows for the formation of a wide range of derivatives, making it a valuable starting material in the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
2-Bromopyridine-4-carboxylic acid is used as a key intermediate in the development of pharmaceutical compounds. Its versatile chemical properties enable the creation of new drugs with potential therapeutic applications, such as those targeting neurological disorders, cancer, and other diseases.
Used in Chemical Processes:
2-Bromopyridine-4-carboxylic acid is employed as a reagent in various chemical processes, including the synthesis of dyes, pigments, and other specialty chemicals. Its ability to participate in a range of chemical reactions makes it a valuable component in the production of these materials.

InChI:InChI=1/C6H4BrNO2/c7-5-3-4(6(9)10)1-2-8-5/h1-3H,(H,9,10)/p-1

Upstream product

• 4926-28-7 2-Bromo-4-picoline 
• 695-34-1 2-Amino-4-methylpyridine 
• 1333-82-0 chromium(VI) oxide 
• 6313-54-8 2-chloroisonicotinic acid, 
• 26156-48-9 methyl 2-bromoisonicotinate 

Downstream Products

• 26156-48-9 methyl 2-bromoisonicotinate 
• 855636-36-1 2-isobutoxy-isonicotinic acid 
• 89978-52-9 2-bromo-4-carboxylic acid ethyl pyridine 
• 118289-16-0 (2-bromopyridin-4-yl)methanol 
• 77314-81-9 2-(dimethylamino)pyridine-4-carboxylic acid 
• 566198-32-1 2-(4-formylphenyl)-isonicotinic acid 
• 259817-68-0 N-(2-bromoisonicotinoyl)-3-(3,4-dimethoxyphenyl)-L-alanine ethyl ester 
• 855153-75-2 2-(piperidin-1-yl)isonicotinic acid 
• 209262-38-4 (2S)-2-(2-bromoisonicotinoylamino)-3-(3,4-dimethoxyphenyl)-1-propanol 
• 209262-39-5 (2S)-2-{2-[4-(3-pyridyl)phthalazin-1(2H)-on-2-yl]isonicotinoylamino}-3-(3,4-dimethoxyphenyl)-1-propanol 
• 209261-87-0 N-[2-(3,4-dimethoxy-phenyl)-1-hydroxymethyl-ethyl]-2-(1-oxo-4-pyrimidin-5-yl-1H-phthalazin-2-yl)-isonicotinamide 
• 209261-52-9 (3S)-4-(3-acetoxymethyl-3,4-dihydro-6,7-dimethoxyisoquinolin-1-yl)-2-[4-(3-pyridyl)phthalazin-1(2H)-on-2-yl]pyridine 
• 209261-90-5 N-[2-(3,4-dimethoxy-phenyl)-1-hydroxymethyl-ethyl]-2-(1-oxo-4-pyridin-3-ylmethyl-1H-phthalazin-2-yl)-isonicotinamide 
• 775268-27-4 acetic acid 6,7-dimethoxy-1-[2-(1-oxo-4-pyrimidin-5-yl-1H-phthalazin-2-yl)-pyridin-4-yl]-3,4-dihydro-isoquinolin-3-ylmethyl ester 

Relevant articles and documents

Metal-induced dynamic conformational and fluorescence switch of quinone-appended Zn-porphyrin

In this report, we have designed and synthesized a novel switching molecule whose fluorescence can be switched via dynamic conformational change between expanded and shrunk states induced by metal complexation and decomplexation. The switching molecule is composed of three kinds of components, namely, a Zn2+-porphyrin fluorophore, two quinone quenchers, and their linkers containing a 4,4′-bipyridine moiety. UV-vis and fluorescence titration studies revealed that metal complexation of the bipyridine units with Zn2+ ions induced the dynamic structural change of the molecular shape and simultaneous enhancement of fluorescence of the Zn2+-porphyrin fluorophore.

Dual Reactivity of 1,2,3,4-Tetrazole: Manganese-Catalyzed Click Reaction and Denitrogenative Annulation

A general catalytic method using a Mn-porphyrin-based catalytic system is reported that enables two different reactions (click reaction and denitrogenative annulation) and affords two different classes of nitrogen heterocycles, 1,5-disubstituted 1,2,3-triazoles (with a pyridyl motif) and 1,2,4-triazolo-pyridines. Mechanistic investigations suggest that although the click reaction likely proceeds through an ionic mechanism, which is different from the traditional click reaction, the denitrogenative annulation reaction likely proceeds via an electrophilic metallonitrene intermediate rather than a metalloradical intermediate. Collectively, this method is highly efficient and offers several advantages over other methods. For example, this method excludes a multi-step synthesis of the N-heterocyclic molecules described and produces only environmentally benign N2 gas a by-product.

1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The novel compounds have formula (I): (Formula (I)) or are pharmaceutically acceptable salts thereof, wherein: R1a, R1b, R1c, R1d, R1e and R1f each independently represent hydrogen, optionally substituted C1-C6 alkyl or optionally substituted C3-C4 cycloalkyl, or R1b and R1c together form an optionally substituted C3-C6 cycloalkyl ring, or R1d and R1e together form an optionally substituted C3-C6 cycloalkyl ring; R2 represents hydrogen or optionally substituted C1-C6 alkyl; A represents an optionally further substituted 5 to 10 membered monocyclic or bicyclic heteroaryl, heterocyclyl or aryl ring; L represents a covalent bond or linker; B represents an optionally substituted 3 to 10 membered monocyclic or bicyclic heterocyclyl, heteroaryl, cycloalkyl or aryl ring; and when -A-L-B is at position x attachment to A is via a carbon ring atom of A, and either: A cannot be triazolopyridazinyl, triazolopyridinyl, imidazotriazinyl, imidazopyrazinyl or pyrrolopyrimidinyl; or B cannot be substituted with phenoxyl; or B cannot be cyclopentyl when L is an oxygen atom.

Iron(II)-Based Metalloradical Activation: Switch from Traditional Click Chemistry to Denitrogenative Annulation

A unique concept for the intermolecular denitrogenative annulation of 1,2,3,4-tetrazoles and alkynes was discovered by using a catalytic amount of Fe(TPP)Cl and Zn dust. The reaction precludes the traditional, more favored click reaction between an organic azide and alkynes, and instead proceeds by an unprecedented metalloradical activation. The method is anticipated to advance access to the construction of important basic nitrogen heterocycles, which will in turn enable discoveries of new drug candidates.

Design and synthesis of non-symmetric phenylpyridine type ligands. Experimental and theoretical studies of their corresponding iridium complexes

In this work three non-symmetric phenylpyridine type ligands, L1, L2 and L3, were designed, and their corresponding Iridium complexes, C1, C2 and C3, synthetized, in order to understand the effect of ligand asymmetry on the properties of the complexes, and to explore their potentiality in devices. The complexes were structurally characterized by NMR experiments and by X-ray Diffraction, and physicochemically by technics as UV/Vis and cyclic voltammetry. Theoretical DFT calculations of the energy and electronic density of the frontier orbitals of the complexes under study were also performed. The energy of the HOMO and LUMO correlated well with the experimental electrochemical data, and supported the understanding of the processes observed.

N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions there-of; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal

N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.

CYCLOMETALATED DYE COMPLEXES AND THEIR USE IN DYE-SENSITIZED SOLAR CELLS

The present invention provides a modular approach to preparing a large array of substituted cyclometalated compounds which behave as dyes having intense absorbance bands in the visible spectrum The compounds include at least one terpyridine-type ligand (tpy) and one cyclometalated tridentate ligand having the bonding motif N,C,N' or C,N, N'. In particular, compounds of formula (I) and formula (II), as shown, where M and R1 to R4 are as defined herein, are disclosed The utility of these compounds in dye-sensitized solar cells (DSSCs) is also taught.

Benzothiazole Formulations and Use Thereof

The present invention is related to macrogol glyceride pharmaceutical formulations containing benzothiazole derivatives. In particular, the invention is related to benzothiazole stearoyl macrogol pharmaceutical formulations, method of preparation and use thereof.

4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES

A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRx or CRxRy; if X=NRx then n is 1 or 2 and if X=CRxRy then n is 1; Rx is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry is selected from H, hydroxy, amino; or Rx and Ry may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRxRy, RC1, RC2, Rx and Ry, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: (i) formula (i), where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; and (ii) formula (ii), where Q is O or S.